(208 days)
Not Found
Not Found
No
The description focuses on the use of control slides for staining reagents in cell culture assays and does not mention any computational analysis or algorithms, let alone AI/ML.
No
The device is described as a quality control material used to confirm the accuracy of staining reagents in cell culture confirmatory assays for the detection of HSV-1. It does not provide treatment or directly impact a patient's health.
No
This device is described as a quality control material used to confirm the accuracy of staining reagents in cell culture confirmatory assays for HSV-1 detection. It provides positive and negative controls for the staining process, rather than directly diagnosing a patient's condition.
No
The device is described as physical slides containing fixed cells, which are hardware components, not software.
Based on the provided information, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states that the device is used as "quality control materials used to confirm the accuracy of staining reagents used in cell culture confirmatory assays for the detection of HSV-1." This clearly indicates its use in an in vitro diagnostic procedure (testing samples outside the body).
- Function: The device provides positive and negative controls for staining reagents used in a diagnostic test for HSV-1. This function is directly related to ensuring the reliability and accuracy of an in vitro diagnostic assay.
- Care Setting: The intended user is "Laboratories," which is a typical setting for performing in vitro diagnostic tests.
While the document doesn't explicitly state "In Vitro Diagnostic Device," the intended use and function align perfectly with the definition of an IVD. It is a reagent/control used in vitro to support a diagnostic test.
N/A
Intended Use / Indications for Use
HSV-1 Antigen Control Slides are quality control materials used to confirm the accuracy of staining reagents used in cell culture confirmatory assays for the detection of HSV-1. Each individual slide contains two wells of fixed cells, one HSV-1 infected well and one uninfected well. The two wells of cells on the HSV-1 Antigen Control Slide are stained concomitantly with the cells inoculated with patient sample providing both a positive and negative control for the staining reagents and procedure. Lack of staining of the positive well indicates a failure of one or more components of the staining reagent.
Product codes
GQN
Device Description
Not Found
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Not Found
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Not Found
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 866.3305 Herpes simplex virus serological assays.
(a)
Identification. Herpes simplex virus serological assays are devices that consist of antigens and antisera used in various serological tests to identify antibodies to herpes simplex virus in serum. Additionally, some of the assays consist of herpes simplex virus antisera conjugated with a fluorescent dye (immunofluorescent assays) used to identify herpes simplex virus directly from clinical specimens or tissue culture isolates derived from clinical specimens. The identification aids in the diagnosis of diseases caused by herpes simplex viruses and provides epidemiological information on these diseases. Herpes simplex viral infections range from common and mild lesions of the skin and mucous membranes to a severe form of encephalitis (inflammation of the brain). Neonatal herpes virus infections range from a mild infection to a severe generalized disease with a fatal outcome.(b)
Classification. Class II (special controls). The device is classified as class II (special controls). The special control for the device is FDA's revised guidance document entitled “Class II Special Controls Guidance Document: Herpes Simplex Virus Types 1 and 2 Serological Assays.” For availability of the guidance revised document, see § 866.1(e).
0
、川_ -1 1097
Class III Summary
Type of Problems:
-
Loss of biological activity caused by antigenic deterioration.
-
Loss (Removal) of the fixed cells in either the infected or uninfected slide wells.
HSV-1 Antigen Control slides are to be used by laboratories to determine the activity of staining reagents. If the HSV-1 Antigen Control Slides had deteriorated to a point of non-reactivity or the cells had dislodged and were subsequently used by a laboratory, the indication would be that the staining reagents were not working properly. This would cause the test to be discarded but would not lead to a false positive or false negative clinical test result.
1
5171 Wilfong Road, Memphis, Tennessee 38134-5611 Phone (901) 382-8716
FAX (901) 382-0027
Date 3-10-97
510(k) Reference Number - K964874
Device name: HSV-1 Antigen Control Slides
I certify, that in my capacity as Vice President of Regulatory Affairs, of Viral Antigens, Inc. that I have conducted a reasonable search of all information known or otherwise available about the types and causes of safety or effectiveness problems that have been reported for HSV-1 Antigen Control Slides. I further certify that I am aware of the types of problems to which HSV-1 Antigen Control Slides is susceptible and that, to the best of my knowledge . the following summary of the types and causes of safety or effectiveness problems about HSV-1 Antigen Control Slides is complete and accurate.
Class III Certification
Tony S Ratcliffe
Terry S. Ratcliffe VP Regulatory Affairs
2
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three stripes forming its wing and tail feathers. The eagle is enclosed in a circle with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" around the perimeter of the circle.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Terry S. Ratcliffe Vice President Regulatory Affairs Viral Antigens, Inc. 5171 Wilfong Road Memphis, TN 38134
. ॥ ॥ 1 1007
Re: K964874
Trade Name: HSV-1 Antigen Control Slides Regulatory Class: III Product Code: GQN Dated: January 14, 1997 Received: January 15, 1997
Dear Mr. Ratcliffe:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: General (GMP) regulation (21 CFR Part 820) and that, through neriodic GMP inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal Laws or Regulations.
3
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770)488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits vour device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number (800) 638-2041 or at (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html"
Sincerely yours.
Steven Sutman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
510(k) Reference Number - K964874
Device name: __ HSV-1 Antigen Control Slides
INDICATIONS FOR USE:
In order to confirm HSV-1 infections physicians frequently use tissue culture techniques. This involves obtaining patient samples, inoculation of these samples into established cell lines (Such as MRC-5 cells) and monitoring these cells for HSV-1 induced cytopathology. Frequently the cells inoculated with patient sample are then stained as an aid in the diagnosis of HSV-1 infections.
HSV-1 Antigen Control Slides are quality control materials used to confirm the accuracy of staining reagents used in cell culture confirmatory assays for the detection of HSV-1. Each individual slide contains two wells of fixed cells, one HSV-1 infected well and one uninfected well. The two wells of cells on the HSV-1 Antigen Control Slide are stained concomitantly with the cells inoculated with patient sample providing both a positive and negative control for the staining reagents and procedure. Lack of staining of the positive well indicates a failure of one or more components of the staining reagent.
Kharme Muisely de Mason Hanson
vision Sign-Off Division of Clinical Laboratory Devices 510(k) Number
Prescription Use (Per 21 CFR 801.109)